

# **OptimiseRx**

Fully integrated with the patient record to enable the delivery of prescribing best practice and to optimise cost savings.



## At a Glance

OptimiseRx delivers Best Practice, Safety and Cost Swap reference messages directly into the prescribing workflow. It is fully integrated with the patient record and can assist in the delivery of increased / high message acceptance rates by providing suggestions for alternative medications which may be clinically appropriate for each individual patient according to their clinical record. Alternative suggestions are prescreened for drug-drug interactions, contraindications and patient sensitivities as per the coded entries in the patient record.

## **Prerequisites**

OptimiseRx must be activated within your practice before it is available within SystmOne, please see the "Installation Guide - SystmOne" for details of how to activate OptimiseRx. This guide is available from your CCG.

## **Prescribing Workflow**

OptimiseRx is fully integrated into the prescribing workflow within SystmOne. Messages are only triggered when the patient's demographic details and history of medications, conditions and test results all combine to flag a message as appropriate to that specific patient at that point in time.

Examples of the patient attributes that are analysed to trigger a given message can include:

Age, Gender, Medication history, Historical conditions, Presenting complaint, Allergies, Measures and observations, Dosing regimens, BMI, Blood pressure, FEV1, Red blood cell count, Cardiovascular risk, Cholesterol, Ethnicity, Neutrophil count, Creatinine clearance, DEXA T-Score.

## **Best Practice and Safety Messages**

Messages relating to Best Practice, Safety, Therapeutic Interchanges and any messages with multiple alternatives are triggered at the point of entering a new medication into the prescribing window. Once a drug is selected the patient's profile is analysed and any appropriate messages are returned.

These messages provide links out to the authoritative source of the guidance or safety indicator displayed so that the prescriber has access to the original source of the guidance. The message might suggest multiple alternative medications that may be used instead of the original medication and, subject to CCG conditions, these may be filtered so that only those medications that are locally approved can be selected from this screen.

Figure 1 on the following page details the various aspects of the Best Practice dialog box and the actions that can be taken.

**Disclaimer:** The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.

		Click ett	ier of these boxes	to overfule the messo
OptimiseR: Warnings for Lactul	ose 3.1-3.7a/5ml oral solution			
▼ Expand All Collapse	All	Rest All Warnings	X Overrule All with	Reason & Overrule A
0			11	X
Consider prescribing	a macrogol instead of lact	Show 5 Si	uggestions 🗱 Overru	e with Reason 🗱 Overrul
NICE (Cochrane Quality and Pr Cochrane review concluded that ief of abdominal pain, and the	oductivity topics) recommends a it treatment with macrogols is sup need for additional products in ch	macrogol in preference to la perior to lactulose in outcom ronic constipation. This is a	ctulose for the treatm es of stool frequency QIPP Key Therapeutic	ent of chronic constipation ber week, form of stool, Topic.
terences NICE NICE	Click off the liftks to see	the original source of t	le guidandce	
ny is this warning showing?	Click here to see why the click here to s	ne message has been tr	iggered	
Leizzara The Outbridge By module in				
laimer: The OptimiseRx module is	intended for the use of healthcase pr	rofessionals and provided on th	e basis that the healthca	re professionals will retain
laimer: The OptimiseRx module is and SOLE responsibility for decid	intended for the use of healthcase pr ing what treatment to prescribe or dis	rofessionals and provided on th spense for any particular patient	e basis that the healthca or circumstance View f	re professionals will retain Full Disclaimer
laimer: The OptimiseRx module is . and SOLE responsibility for decid	intended for the use of healthcase pr ing what treatment to prescribe or dis Proceed with <u>Alternative</u>	rofessionals and provided on the pense for any particular patient proceed with Original	e basis that the healthca or circumstance View f	re professionals will retain Full Disclaimer
laimer: The OptimiseRx module is . and SOLE responsibility for decid	intended for the use of healthcase pr ling what treatment to prescribe or dis Proceed with Alternative	rofessionals and provided on the pense for any particular patient Proceed with Original	e basis that the healthca or circumstance View f	re professionals will retain Full Disclaimer

Figure 1 : Best Practice dialog box

As seen in Figure 1 above, OptimiseRx messages are structured to provide:

- Headline message text so the key message is rapidly understood;
- **Brief description** or summary of the guidance allowing the prescriber to summarise and become familiar with the guidance without needing to click further;
- Access to the local or national guidance via direct hyperlinks to the authoritative source of the guidance, providing additional detail via a single click to validate the relevance to an individual patient.
- The **patient attributes** in the record which led to the message being presented, accessed via the 'Why is this warning showing?' hyperlink.

# To ACCEPT a Best Practice Message with Alternative Suggestions

<ul> <li>Expand All</li> </ul>	Collapse All	Reset All Warnings	🗱 Overrule All with Reason	🗱 Overrule A
--------------------------------	--------------	--------------------	----------------------------	--------------

#### Figure 2 : Show alternative suggestions

- 1. Click 'Show Suggestions' button as shown in Figure 2 above
- 2. The alternatives dialog box is then shown, as in Figure 3 below
- 3. Select the alternative you wish to proceed with and click 'Ok'

#### Figure 3 : List of alternative suggestions

Suggested Medication			×
Consider prescribing a mad	rogol instead of	lactulose	
NICE (Cochrane Quality and Producti Cochrane review concluded that treatm abdominal pain, and the need for additi References NICE NICE Why is this warning showing?	vity topics) recommend: ent with macrogols is si onal products in chronic	s a macrogol in preference to lactulose for the treatme uperior to lactulose in outcomes of stool frequency per c constipation.This is a QIPP Key Therapeutic Topic.	nt of chronic constipation. A week, form of stool, relief of
Suggested Products			
I Hide 0 drugs with warnings	Click h	ere to reveal alternatives that have been hidd	en
Product V	Presentation	Warnings	
macrogol compound concentrate for oral solution macrogol compound npf half strength oral powder sugar-free macrogol compound npf oral powder macrogol compound npf oral powder sugar-free	List of su 1. Click of 2. Click of 2. Click of 2. Click of 2. Click of 2. Click of 2. Click of su	uggested alternatives on the chosen alternative 'Ok' to proceed	
5 Suggested Products			

### **Hidden Alternatives**

As noted in figure 3 above (page 4) SystmOne will hide medicines from the list of alternatives where those medicines have been identified as having warnings associated with them. The warnings are triggered by data explicitly coded within the patient record, and take the form of drug-drug interactions, contraindicated medicines and patient sensitivities.

In order to make the hidden medicines selectable you must first unhide them, this is achieved by clicking on the tick-box titled 'Hide *n* drugs with warnings', this will un-tick the box and the hidden alternatives will be shown.

Y Suggested Medication		×
Consider prescribing sin	nvastatin, or other low cost stat	tin
<ul> <li>NICE guidance for Type 2 diabete primary CVD prevention. Treatment a low non-hyperglycaemia related (</li> <li>QIPP recommends that prescribi References NICE NICE Diabete Why is this warning showing?</li> </ul>	es (CG87) recommends that patients with type should be initiated with generic simvastatin ( CV risk should be assessed using the UKPD ng of lipid lowering agents is reviewed to ens tes Trial Unit	e II diabetes who are over 40 years of age should be offered to 40mg) or a statin of similar efficacy and cost. Individuals with S risk engine and treated if their 10-year CV risk exceeds 20%. ure it is in line with NICE guidance.
Suggested Products		
Hide 5 drugs with warnings	Un-tick this box to show hidden alte	rnatives
Product V	Presentation	Warnings
simvastatin	10mg tablets	CONDITION: Renal impairment - creatinine clearance below + 30 ml/minute
simvastatin	20mg tablets	CONDITION: Renal impairment - creatinine clearance below 30 ml/minute
simvastatin	20mg/5ml oral suspension sugar-free	CONDITION: Renal impairment - creatinine clearance below 30 ml/minute
simvastatin	40mg tablets Alternatives with warning	CONDITION: Renal impairment - creatinine clearance below s are shown in the list greyed-out and the details of
simvastatin	40mg/s the associated warning	s are shown in the 'Warnings' column to the right 30 ml/minute
Select an alternative by clives 5 Suggested Products	cking on it, then clicking 'Ok'	-
	Qk Cance	

Figure 4 : Selecting hidden alternative suggestions

## To REJECT a Best Practice Message

Expand All     Collapse All	Re Re	eset All Warnings	🗱 Ove	errule All with Reason	🗱 Overrule A
-----------------------------	-------	-------------------	-------	------------------------	--------------

#### Figure 5 : Overrule a message

To reject a message you can either:

• Overrule the message

Or...

- Overrule the message with a reason, whereby you can either:
  - Choose from one of the pre-defined reasons (Figure 6 below)
  - Select 'Other Reason' and key in your own reasons for overruling the message

Show 5 Suggestions	<b>*</b> c	overrule with Reason	🗱 Overrule
preference to lactulose for		Disagree with rule Not suitable for this p	atient
ation.This is a QIPP Key T		Data missing from pat	tient record
		Initiated by specialist Temporary resident	
		Other Reason	

#### reason

Figure 6 : Overrule a message with a given

All overruled message reasons are visible by the CCG, this is a valuable communication tool to assist in facilitating messages you are presented with are appropriate for your patient population.

### **Cost Messages**

These messages inform you that a single cheaper alternative is available based on the potential savings that can be made. Suggested alternatives are validated for clinical appropriateness according to the coded patient record and may be filtered to include only those medications that are locally approved.

These messages use the total dosing supply quantity to calculate the savings, they will be triggered once the issue duration has been completed.

CoptimiseRx Cost Savings for Nitrofurantoin 50mg tablets					<b>X</b>
Original				Suggested	
Nitrofurantoin 50mg tablets 28 tablets Generic £28.26	•	Nitrofurantoi 28 capsules Generic £3.42	in 50mg c	apsules	
<b>Disclaimer:</b> The OptimiseRx module is intended for the use of healthcase p FULL and SOLE responsibility for deciding what treatment to prescribe or d Use <u>O</u> riginal	professiona lispense for <u>Use A</u> lter	Is and provided any particular p native <u>C</u>	on the bas patient or ci ancel	Total saving is that the healthcare profession rcumstance View Full Disclain	£24.84 als will retain ner

#### Figure 7 : Cost message

- To proceed with the alternative click the 'Use Alternative' button, the suggested drug will replace the original drug in the prescribing screen, proceed as normal to complete the prescription.
- Selecting the 'Use Original' button will ignore the message and proceed to prescribe the original drug.

## **RAG / Formulary Messages**

If your CCG has chosen to implement messages to support the local formulary, you may see these



infor

#### Figure 8 : Example of a Red RAG status formulary message

This example shows a red banner indicating the drug should not be routinely prescribed in primary care. The message may include a link to the local formulary allowing you to quickly access the full formulary for further

# Using the FDB ORx (OptimiseRx) Button

OptimiseRx can be run against any given patient outside of the prescribing workflow, supporting medicines use review and allowing prescribers to identify opportunities for optimising all current prescriptions for any given patient, a useful analysis tool for complex multi-morbidity and polypharmacy patients.

The OptimiseRx button needs to be configured before use, please see the "Installation Guide—SystmOne" for details of how to achieve this. This guide is available from your CCG.

### Using the OptimiseRx button

Once the button has been installed, load a patient record into SystmOne and simply click on the button:



#### button added to the toolbar

This will review the patient record against all OptimiseRx messages and return the results to you in a summary window. The screen shot below shows two messages have been returned, one relating to the patients current repeat medications and one suggesting a new medication to commence, this is based on the details present in the patient's medical record:

OptimiseRx Results		×
Current Repeat Medication		
Aspirin 75mg dispersible tablets 28 tablet - take one daily	View 1 Best Practice Warnings	View Cheaper Alternative
Suggested Medication		
Consider prescribing a calcium supplement	View 1 Best Practice Warnings	View Cheaper Alternative

Figure 10 : Results screen

To view the details for each item returned click on the relevant action box beside the message, the action box may represent a Best Practice message or a Cost related message:

#### **Current Repeat Medication**

Aspirin 75mg dispersible tablets 28 tablet - take one daily

View 1 Best Practice Warnings View Cheaper Alternative

#### Figure 11 : Accessing the details behind the summary result messages

Clicking on the action button (as highlighted above) will open the message dialog in the same manner as the messages presented within the prescribing workflow, along with all appropriate options to enable prescriptions to be raised by accepting the message.

If there are no results to return for a patient the following notification box will be shown:



## Support

If your query is in relation to any clinical material or information you should refer to your Medicines Management Team at your CCG.

If your query is related to system functionality or SystmOne itself please follow your local helpdesk procedures.

### Visit fdbhealth.co.uk

First Databank (FDB), a subsidiary of Hearst Corporation, is the UK's leading provider of drug knowledge bases and active clinical decision support.

As the company that helped to launch the medication decision support industry, we offer more than three decades of experience in helping transform drug knowledge into actionable, targeted and effective solutions geared to improving patient care, patient safety and outcomes.





Swallowtail House, Grenadier Road, Exeter Business Park, Exeter EX1 3LH Tel +44 (0) 1392 440 100 • Fax +44 (0) 1392 440 192 • fdbhealth.co.uk Other Locations: San Francisco, California • Indianapolis, Indiana • St. Louis, Missouri



NICE has accredited the process used by First Databank to develop content used in Multilex drug knowledge. More information on accreditation can be found at www.nice.org.uk/accreditation. Accreditation evaluates only the processes used to develop content and excludes recommendations displayed by decision support systems in specific clinical settings as these are dependent on technical algorithms which are outside of the scope of NICE accreditation. Accreditation can be used to inform compliance with ISB 0129 - Clinical Safety Risk Management System - Manufacture of Health Software and ISB 0160 - Clinical Safety Risk Management System - Deployment and Use of Health Software, but cannot be used in isolation to release any product for clinical use.